Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: September 2012 (Document dated September 5, 2012)
Purpose: Notification of the publication of a Registration Document approved by the UK Listing Authority regarding a new debt issuance program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, existing debt levels, or liquidity ratios. This document serves as a notice of a new financing program rather than a financial results report.
Material Changes and New Programs
- New Debt Program: Establishment of a £15,000,000,000 (15 billion GBP) Euro Medium Term Note Programme.
- Entities Involved: The program involves GlaxoSmithKline plc, GlaxoSmithKline Capital plc, and GlaxoSmithKline Capital Inc.
- Regulatory Status: The Registration Document was approved by the UK Listing Authority on September 5, 2012.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no operational guidance, earnings outlook, or management commentary on business performance.
Risks and Contingencies: The document includes a standard disclaimer stating that the Registration Document is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions. Investors must verify their eligibility to access the information.
Investor Verification Checklist
- Verify the full terms of the £15 billion Euro Medium Term Note Programme in the Registration Document.
- Confirm eligibility to access the Registration Document based on country of residence as specified in the filing.
- Locate the Registration Document via the National Storage Mechanism at www.Hemscott.com/nsm.do.
- Note that this filing does not contain updated financial performance data; refer to the most recent Form 20-F or quarterly reports for financial metrics.